HK1039489A1 - New piperazine and piperidine compounds. - Google Patents

New piperazine and piperidine compounds.

Info

Publication number
HK1039489A1
HK1039489A1 HK02100871A HK02100871A HK1039489A1 HK 1039489 A1 HK1039489 A1 HK 1039489A1 HK 02100871 A HK02100871 A HK 02100871A HK 02100871 A HK02100871 A HK 02100871A HK 1039489 A1 HK1039489 A1 HK 1039489A1
Authority
HK
Hong Kong
Prior art keywords
piperidine compounds
new piperazine
piperazine
new
piperidine
Prior art date
Application number
HK02100871A
Other languages
English (en)
Inventor
Roelof W Feenstra
Van Der Johannes A M Heijden
Johannes Mos
Stephen K Long
Gerben M Visser
Cornelis G Kruse
Van Gustaaf J M Scharrenburg
Anne G Toorop
Gerrit P Toorop
Original Assignee
Duphar Int Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8234340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1039489(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duphar Int Res filed Critical Duphar Int Res
Publication of HK1039489A1 publication Critical patent/HK1039489A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK02100871A 1998-11-13 2002-02-05 New piperazine and piperidine compounds. HK1039489A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203871 1998-11-13
PCT/EP1999/008702 WO2000029397A1 (en) 1998-11-13 1999-11-10 New piperazine and piperidine compounds

Publications (1)

Publication Number Publication Date
HK1039489A1 true HK1039489A1 (en) 2002-04-26

Family

ID=8234340

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02100871A HK1039489A1 (en) 1998-11-13 2002-02-05 New piperazine and piperidine compounds.

Country Status (28)

Country Link
US (1) US6780864B1 (pt)
EP (1) EP1131308B1 (pt)
JP (1) JP3638874B2 (pt)
KR (1) KR100619465B1 (pt)
CN (1) CN1225462C (pt)
AR (1) AR021256A1 (pt)
AT (1) ATE267183T1 (pt)
AU (1) AU756470B2 (pt)
BR (1) BR9915293B1 (pt)
CA (1) CA2350137C (pt)
CZ (1) CZ299774B6 (pt)
DE (1) DE69917478T2 (pt)
DK (1) DK1131308T3 (pt)
DZ (1) DZ2934A1 (pt)
ES (1) ES2217833T3 (pt)
HK (1) HK1039489A1 (pt)
HU (1) HUP0104922A3 (pt)
IL (2) IL143028A0 (pt)
MX (1) MXPA01004854A (pt)
NO (1) NO318888B1 (pt)
NZ (1) NZ511584A (pt)
PL (1) PL193685B1 (pt)
RU (1) RU2225406C2 (pt)
SI (1) SI1131308T1 (pt)
SK (1) SK285648B6 (pt)
TW (1) TWI252230B (pt)
UA (1) UA71590C2 (pt)
WO (1) WO2000029397A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73981C2 (en) 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
CN1174979C (zh) * 2000-05-12 2004-11-10 索尔瓦药物有限公司 哌嗪和哌啶化合物
WO2001085168A1 (en) * 2000-05-12 2001-11-15 Solvay Pharmaceuticals B.V. Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
CA2428519A1 (en) * 2000-11-14 2002-05-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists
AR034206A1 (es) * 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
US6800648B2 (en) 2001-04-26 2004-10-05 Wyeth Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-1,6,9-trioxa-3-AZA-cyclopenta[a]naphthalen-2-one
US6743796B2 (en) 2001-05-07 2004-06-01 Wyeth Piperazinyl-isatins
CN1292749C (zh) 2001-07-26 2007-01-03 默克专利股份有限公司 2-[5-(4-氟苯基)-3-吡啶基甲氨基甲基]苯并二氢吡喃及其生理学上可接受的盐的新用途
EP1336406A1 (en) * 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
AU2003244160A1 (en) * 2002-06-25 2004-01-06 Sumitomo Pharmaceuticals Co., Ltd. Novel benzoxazolinone derivative
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
EP1595542A1 (en) * 2004-03-26 2005-11-16 Solvay Pharmaceuticals B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
US7596407B2 (en) 2004-03-26 2009-09-29 Solvay Pharmaceuticals, B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
CA2567909A1 (en) * 2004-05-27 2005-12-15 Ucb, S.A. Benzoxazolone derivatives, processes for preparing them and their uses
US7405216B2 (en) 2004-08-18 2008-07-29 Solvay Pharmaceuticals, B.V. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
US7750013B2 (en) 2005-08-22 2010-07-06 Solvay Pharmaceuticals, B.V. N-oxides as prodrugs of piperazine and piperidine derivatives
RU2394821C2 (ru) * 2005-08-22 2010-07-20 Солвей Фармасьютикал Б.В. N-оксиды как пролекарства производных пиперазина и пиперидина
AR058022A1 (es) * 2005-08-22 2008-01-23 Solvay Pharm Bv Derivados de benzooxazoles, composiciones farmaceuticas y su uso para el tratamiento de desordenes del sistema nervioso.
US8106056B2 (en) 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
UY32934A (es) * 2009-10-12 2011-05-31 Abbott Healthcare Products Bv Monohidrato de pardoprunox
US11103499B2 (en) 2016-08-26 2021-08-31 EXCIVA (UG) (haftungsbeschränkt) Compositions and methods thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567884B1 (fr) 1984-07-19 1987-03-06 Roussel Uclaf Nouveaux derives de l'indole, leur preparation, leur application comme medicaments et les compositions les renfermant
DE3571436D1 (en) * 1984-12-21 1989-08-17 Duphar Int Res New pharmaceutical compositions having anti-psychotic properties
ATE81975T1 (de) * 1984-12-21 1992-11-15 Duphar Int Res Arzneimittel mit psychotroper wirkung.
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
ZA954689B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines
MX9700693A (es) 1994-07-26 1997-04-30 Pfizer Derivados del 4-indol.
CA2250347C (en) * 1996-03-29 2006-02-21 Duphar International Research B.V. Piperazine and piperidine compounds with high affinity for dopamine-d2 and serotonin-5ht1a receptors
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists

Also Published As

Publication number Publication date
BR9915293B1 (pt) 2011-11-01
JP3638874B2 (ja) 2005-04-13
IL143028A (en) 2006-12-10
NZ511584A (en) 2003-01-31
EP1131308B1 (en) 2004-05-19
PL347635A1 (en) 2002-04-22
CZ20011657A3 (cs) 2001-10-17
SK6492001A3 (en) 2001-10-08
DK1131308T3 (da) 2004-06-28
SK285648B6 (sk) 2007-05-03
EP1131308A1 (en) 2001-09-12
CN1225462C (zh) 2005-11-02
UA71590C2 (en) 2004-12-15
CN1378540A (zh) 2002-11-06
CZ299774B6 (cs) 2008-11-19
CA2350137A1 (en) 2000-05-25
ATE267183T1 (de) 2004-06-15
AU756470B2 (en) 2003-01-16
CA2350137C (en) 2008-04-22
DE69917478T2 (de) 2004-09-16
AR021256A1 (es) 2002-07-03
HUP0104922A3 (en) 2003-05-28
KR20010080995A (ko) 2001-08-25
KR100619465B1 (ko) 2006-09-05
RU2225406C2 (ru) 2004-03-10
TWI252230B (en) 2006-04-01
US6780864B1 (en) 2004-08-24
NO20012339L (no) 2001-05-11
BR9915293A (pt) 2001-08-07
IL143028A0 (en) 2002-04-21
SI1131308T1 (en) 2004-10-31
JP2002530276A (ja) 2002-09-17
WO2000029397A1 (en) 2000-05-25
DE69917478D1 (de) 2004-06-24
DZ2934A1 (fr) 2004-03-15
NO20012339D0 (no) 2001-05-11
HUP0104922A2 (en) 2002-08-28
ES2217833T3 (es) 2004-11-01
MXPA01004854A (es) 2005-07-25
PL193685B1 (pl) 2007-03-30
AU1270900A (en) 2000-06-05
NO318888B1 (no) 2005-05-18

Similar Documents

Publication Publication Date Title
HK1039489A1 (en) New piperazine and piperidine compounds.
IL148964A0 (en) Piperazine compounds
DE69902536D1 (en) Polymorphe form von clopidogrel-hydrogenosulfat
EG24743A (en) Heterocyclic compounds.
ZA978194B (en) Piperazine derivatives
ZA986390B (en) Piperazine derivatives
GB2331534B (en) Centralizer
ZA9811345B (en) Piperidine derivatives
ZA985255B (en) Piperazine derivatives
IL126295A0 (en) New piperazine and piperidine compounds
ZA992191B (en) Piperidine derivatives.
GB0017742D0 (en) New case
HK1043998A1 (en) Piperazine derivatives.
IL152177A0 (en) Piperazine and piperidine compounds
IL141166A0 (en) New compounds
ZA9811560B (en) Fungicidal mixtures based on amide compounds and morpholine or piperidine derivatives.
ZA200101830B (en) Piperidine derivatives.
HU9904086D0 (en) New 4-substituted piperidines
ZA991038B (en) Pyrrolidine and piperidine derivatives.
ZA9811491B (en) Fungicidal mixtures based on amide compounds and morpholine or piperidine derivatives.
ZA979781B (en) Piperidine derivatives.
GB0005589D0 (en) New
HUP0101446A3 (en) New compounds
ZA9711284B (en) Piperazine compound.
GB9803376D0 (en) Packer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20121110